Novartis AG Revenue 2006-2018 | NVS

Current and historical revenue for Novartis AG (NVS) from 2006 to 2018. The sum of all revenue fields included for a company's operating activities. The current revenue for Novartis AG as of March 31, 2018 is .
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.237B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $334.531B 16.56
Pfizer (PFE) United States $222.518B 13.69
Merck (MRK) United States $168.755B 15.08
AbbVie (ABBV) United States $152.737B 15.57
Novo Nordisk (NVO) Denmark $121.004B 20.05
Sanofi (SNY) France $104.713B 13.25
GlaxoSmithKline (GSK) United Kingdom $102.153B 13.97
Eli Lilly (LLY) United States $96.679B 19.20
AstraZeneca (AZN) United Kingdom $92.856B 9.72
Bristol-Myers Squibb (BMY) United States $92.237B 18.15